Cedazuridine

立即咨询

Cedazuridine

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1141397-80-9

包装与价格：

包装	价格(元)
10mg	电议
25mg	电议

产品介绍

Cedazuridine (E7727) (Compound 7a) 是一种具有口服活性的胞苷脱氨酶 (CDA) 抑制剂，其 IC50 值为 0.4 μM。Cedazuridine 可用于癌症的研究。

Cas No.

1141397-80-9

别名

E7727

分子式

C₉H₁₄F₂N₂O₅

分子量

268.21

溶解度

DMSO : 50 mg/mL (186.42 mM; ultrasonic and warming and heat to 60°C)

储存条件

4°C, protect from light

General tips

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.

Shipping Condition

Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

产品描述

IC50: 0.4 μM (CDA)^[1]

Cedazuridine (E7727) (Compound 7a) is an orally activecytidine deaminase (CDA)inhibitor with anIC₅₀value of 0.4 μM. Cedazuridine can be used for cancer research^[1].

Cedazuridine (Compound 7a) exhibits superior acid stability^[1].
Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, ) in growth inhibition of AML cell lines^[2].

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models^[2].

Animal Model:	Female NSGS mice, 6-8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models^[2]
Dosage:	3 mg/kg
Administration:	Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:	Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.

Animal Model:	NSGS male mice^[2]
Dosage:	1, 3, 10 and 30 mg/kg
Administration:	Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:	Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.